# Toni K. Choueiri

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/toni-k-choueiri/

## Facts

| Field | Value |
| --- | --- |
| Citations | 123,870 |
| Field | Renal cell carcinoma treatment |
| h-index | 152 |
| i10-index | 912 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5052504518 |
| ORCID iD | 0000-0002-9201-3217 |
| Works | 2,496 |

## Researcher papers

Showing 12 of 30.

- [The Immune Landscape of Cancer](https://scholariq.org/papers/the-immune-landscape-of-cancer/)
- [Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma/)
- [Post-acute COVID-19 syndrome](https://scholariq.org/papers/post-acute-covid-19-syndrome/)
- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://scholariq.org/papers/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma/)
- [Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study](https://scholariq.org/papers/prognostic-factors-for-overall-survival-in-patients-with-metastatic-renal-cell/)
- [Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/pazopanib-versus-sunitinib-in-metastatic-renal-cell-carcinoma/)
- [Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study](https://scholariq.org/papers/clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort-study/)
- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma](https://scholariq.org/papers/clinical-activity-and-molecular-correlates-of-response-to-atezolizumab-alone-or/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.